Eiger Mountains
Corporate Profile
Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of rare diseases. Eiger has built a diverse, late-stage portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, a novel biology for treatment has been identified, and for which an effective therapy is urgently needed. The Eiger management team has extensive experience in the clinical development a... More >>
Stock Quote
EIGR (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$11.89
Change (%) Stock is Down 0.13 (1.08%)
Volume117,299
Data as of 10/19/18 4:00 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle
10/18/18Eiger BioPharmaceuticals to Participate at BTIG Biotech Conference
10/17/18Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
10/16/18Eiger BioPharmaceuticals Announces Phase 2 ULTRA Results of Ubenimex in Lower Leg Lymphedema: Study Did Not Meet Primary or Secondary Endpoint
10/16/18Eiger BioPharmaceuticals Announces Positive Results in Phase 2 PREVENT Study of Avexitide Targeting GLP-1 in Post-Bariatric Hypoglycemia (PBH)
Upcoming EventsMore >>
DateTitle
11/09/18
through
11/13/18
Eiger BioPharmaceuticals at the AASLD (US Liver Meeting)
11/11/18
through
11/15/18
Eiger BioPharmaceuticals at the Obesity Week
11/27/18
through
11/29/18
Eiger BioPharmaceuticals at the Piper Jaffray Healthcare Conference
What's New
There are currently no items available.
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Eiger BioPharmaceuticals posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed.